PitchBook's Q4 report shows biopharma venture capital favoring de-risked assets over platforms and forecasts a continued, disciplined recovery in 2026.
Longevity News
Just as a disciplined soccer player might pass on a hopeful shot in favor of better chance later on, the biopharma ve...
Source: FierceBiotech - Biotech • Published: 19 Feb 2026, 22:00
Continue exploring
Related longevity signals
Nature - MainWill the mRNA flu shot work better than a regular seasonal one? What the science saysAn analysis of Moderna's newly approved mRNA influenza vaccine and the evidence on its efficacy, safety, and reformulation advantages for seasonal flu control.Longevity TechnologyOne-shot FGF21 gene therapy extends mouse healthspanOne-shot FGF21 gene therapy research: a feature-style article previewing an animal study that investigates broad, durable effects on aging. It invites readers curious about systemic metabolic approaches and geroscience implications.Longevity TechnologyBeyond the dashboard: Better health starts with better decisionsA podcast interview examines why abundant health data fails to change behavior and profiles a startup combining multiomic and wearable trends into actionable guidance.Fight Aging!Bacterial Lipoic Acid Protein Ligase A Improves Mammalian Mitochondrial Function and HealthThis article previews research on using a bacterial enzyme to boost mitochondrial protein modification and overall cellular energy, framed as a potential metabolic-enhancing therapy. It invites readers curious about cross-species gene therapy approaches aimed at improving healthspan and age-related function.